Prostate Cancer: A State of The Heart - European Medical Journal
×

Browse

Prostate Cancer: A State of The Heart

|
Urology
Download as | PDF
Chairpeople:
Laurence Klotz1
Speakers:
Alberto Briganti,2 Jan Nilsson,3 Alexandre de la Taille4
Disclosure:

LK – Speaker or advisor: Amgen, Astellas, Dendreon, Ferring, GSK, Janssen, Profound Medical, and Sanofi Aventis; AB – Nothing to disclose; AdlT – Consultant or advisor: Astellas, Ferring, Ipsen, Takeda, and PFM; JN – Consultant or advisor: Boehringer Ingelheim, Probi AB.

Acknowledgements:

Writing assistance provided by Dr Tabasum Mughal.

Support:

Ferring Pharmaceuticals sponsored this symposium. The views and opinions expressed are those of the authors.

Citation
EMJ Urol. ;1[1]:48-53.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

This symposium was focused on reviewing androgen deprivation therapy (ADT) in prostate cancer, highlighting the implications of this therapy in clinical practice and including a focus on the cardiovascular (CV) risk associated with ADT therapy.

Please view the full content in the pdf above.